Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: touching (201), affecting (740), stirring (24)

Carboplatin-Vinorelbine Oral

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC6)-VINORELBINE (Oral) Regimen  NSCLC – Carboplatin (AUC6)-Vinorelbine (Oral) Indication  First line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Vinorelbine-Oral.pdf

Carboplatin(AUC6)-Pemetrexed

Description: Chemotherapy Protocol MESOTHELIOMA CARBOPLATIN (AUC6)-PEMETREXED Regimen • Mesothelioma – Carboplatin (AUC6)-Pemetrexed Indication • First line therapy of advanced pleural mesothelioma where the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/CarboplatinAUC6-Pemetrexed-Ver1.5.pdf

Carboplatin and Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN-PEMETREXED Regimen • NSCLC – Carboplatin-Pemetrexed Indication • First line therapy of stage IIIB
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pemetrexed-Ver1.4.pdf

Radiotherapy for pituitary tumours - patient information

Description: This booklet contains information for patients who have been recommended radiotherapy treatment for a pituitary tumour.
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Radiotherapy-for-pituitary-tumours-3290-PIL.pdf

Lung stereotactic ablative body radiotherapy (SABR) - patient information

Description: This factsheet explains what lung stereotactic ablative body radiotherapy (SABR) is and what to expect during treatment.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Lung-stereotactic-ablative-body-radiotherapy-SABR-2091-PIL.pdf

UHS Our People Strategy 2022 - 2026

Description: OUR PEOPLE STRATEGY 2022 to 2026 CONTENTS 05 Foreword by Steve Harris – chief people officer 06 Our strategic framework 07 Always
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Plans-and-strategies/UHS-Our-People-Strategy-2022-2026.pdf

Going home with a CADD pump - patient information

Description: This factsheet explains what to expect if you are going home with a CADD pump.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Going-home-with-a-CADD-pump-3090-PIL.pdf

Docetaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DOCETAXEL (75) Regimen NSCLC – Docetaxel (75) Indication Second line therapy of stage IIIB
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxelver12.pdf

Cisplatin and Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMETREXED Regimen NSCLC – Cisplatin-Pemetrexed Indication First line therapy of stage III
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CisplatinandPemetrexedver12.pdf

MesoCisPemVer1.3

Description: Chemotherapy Protocol MESOTHELIOMA CISPLATIN-PEMETREXED Regimen Mesothelioma – Cisplatin-Pemetrexed Indication First line therapy of advanced pleural mesothelioma where the disease is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/MesoCisPemVer1.3.pdf

501 to 510 of 546

Previous … 49 50 51 52 53 … Next